“The Missoula Chronic Clinical Cannabis Use Study was proposed to investigate the therapeutic benefits and adverse effects of prolonged use of ‘medical marijuana’ in a cohort of seriously ill patients approved through the Compassionate Investigational New Drug (IND) program of the Food and Drug Administration (FDA) for legal use of cannabis obtained from the National Institute on Drug Abuse (NIDA)… The aim [of this study] was to examine the overall health status of 8 surviving patients in the program. Four patients were able to take part, while three wished to remain anonymous, and one was too ill to participate. Unfortunately, that person, Robert Randall, succumbed to his condition during the course of the study. Thus, 7 surviving patients in the USA remain in the Compassionate IND program…

By 1991, 34 patients were enrolled in the program according to Randall (Randall and O’Leary 1998), while other sources cite the number as only 15. Facing an onslaught of new applications, the Public Health Service (PHS) in the Bush administration closed the program to new patients in March 1992…

The identities of 6 of 8 of the original Compassionate IND program subjects were known to Patients Out of Time.”

Jan. 2002 - Chronic Cannabis Use in the Compassionate IND Program